Reforgene ranks in Guangzhou's 2024 Top 10 science and technology leaders

Recently, the Guangzhou Financial Development Service Center released the list of selected enterprises and institutions for the 2024 Guangzhou pre-IPO "Bellwether" enterprises and outstanding private equity investment institutions. Guangzhou Reforgene Medicine Co., Ltd. ("Reforgene"), on the strength of its outstanding overall capabilities and strong scientific and technological innovation capacity, was successfully selected into the "2024 Guangzhou Top 10 Strongest Science and Technology Bellwethers". The list is guided by the Office of the Financial Committee of the CPC Guangzhou Municipal Committee, and jointly evaluated by the Guangzhou Financial Development Service Center together with ICBC Guangzhou Branch, Postal Savings Bank of China Guangzhou Branch, GF Securities Co., Ltd., Guangdong Equity Exchange Center and venture capital institutions from the Guangdong-Hong Kong-Macao Greater Bay Area, aiming to consolidate and enhance the "Bellwether" brand of high-quality corporate listings, vigorously develop new quality productive forces, cultivate new quality listed companies through multiple measures, strengthen private equity investment to support the growth of Guangzhou enterprises, and identify and cultivate a group of pre-IPO enterprises with "Bellwether" attributes.

Reforgene is a leading innovative gene editing drug company in China, driven by gene editing technology and dedicated to bringing novel medicines to life. Since its establishment, the company has upheld the spirit of innovation, adhered to the dual-drive strategy of breakthroughs in underlying gene editing technology and innovative drug R&D, continuously improved its core competitiveness, and provided global patients with first-in-class and best-in-class innovative medicines. This selection into the Guangzhou Top 10 Strongest Science and Technology Bellwethers is not only recognition of Reforgene's overall strength, but also affirmation of its sustained innovation and pursuit of excellence.

This award is both an honor and an encouragement. In future development, Reforgene will always take innovation as its foundation, deepen its presence in the gene editing medicine field, continuously enhance its innovation capability and market competitiveness, strive to grow into an innovative drug company with global influence, and bring cutting-edge biotechnology to the benefit of human health.